



RETRACTION

Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study [Retraction]

Ouyang T, Liu J, Shi C, Zhu L, Guo X. *J Hepatocell Carcinoma*. 2021;8:1459–1471.

At the authors request, the Editor and Publisher of *Journal of Hepatocellular Carcinoma* wish to retract the published article. On review of the patient records the authors found patients who received cTACE plus apatinib treatment between Jun 2015 to Dec 2015 were not included in the study, resulting in errors in the timing of overall survival (OS) and progression-free survival (PFS) analysis. In addition, there were 10 patients in the DEB-TACE plus apatinib group who received cTACE treatment prior to receiving DEB-TACE treatment and they should have been excluded from the study. In the analysis of Treatment-Related Adverse Events, the Fisher's test and adjusted chi-square test should have been used rather than the chi-squared test, because this was better suited to the expectations of the adverse events observed. The errors found in the methods and analysis resulted in misleading statistical results and the findings being unreliable.

The authors requested for the article to be retracted and apologise for these errors.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

Journal of Hepatocellular Carcinoma

Dovepress

Publish your work in this journal

The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal that offers a platform for the dissemination and study of clinical, translational and basic research findings in this rapidly developing field. Development in areas including, but not limited to, epidemiology, vaccination, hepatitis therapy, pathology and molecular tumor classification and prognostication are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal>

<https://doi.org/10.2147/JHC.S359875>

Journal of Hepatocellular Carcinoma 2022:9 27

27

Received: 25 January 2022
Accepted: 25 January 2022
Published: 28 January 2022



© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).